Synapse - Dean Bajorin

Results (660)

Comparison of somatic mutation profiles from cell free DNA (cfDNA) versus tissue in metastatic urothelial carcinoma (mUC)

Meeting Abstract

Cheng, M. L.; Shady, M.; Cipolla, C. K.; Funt, S.; Arcila, M. E.; Al-Ahmadie, H.; Rosenberg, J. E.; Bajorin, D. F.; Berger, M. F.; Tsui, D.; more...
Journal of Clinical Oncology (2017)

Fulltext@MSK | Save

Genomic comparison of matched primary and metastatic germ cell tumors (GCT)

Meeting Abstract

Audenet, F.; Donoghue, M.; Pietzak, E. J.; Isharwal, S.; Cheng, M. L.; Iyer, G.; Funt, S.; Bajorin, D. F.; Al-Ahmadie, H.; Reuter, V. E.; more...
Journal of Clinical Oncology (2017)

Fulltext@MSK | Save

Single arm phase I/II study of everolimus and intravesical gemcitabine in patients with primary or secondary carcinoma in situ of the bladder who failed bacillus Calmette Guerin (NCT01259063)

Journal Article

Dalbagni, G.; Benfante, N.; Sjoberg, D. D.; Bochner, B. H.; Donat, S. M.; Herr, H. W.; McCoy, A. S.; Fahrner, A. J.; Retinger, C.; Rosenberg, J. E.; more...
Bladder Cancer (2017)

Fulltext@MSK | Save

Keynote-045: Open-label, phase 3 study of pembrolizumab versus investigator's choice of paclitaxel, docetaxel, or vinflunine for previously treated advanced urothelial cancer

Meeting Abstract

Quinn, D.; Bellmunt, J.; de Wit, R.; Vaughn, D. J.; Fradet, Y.; Lee, J. L.; Fong, L.; Vogelzang, N. J.; Climent, M. A.; Petrylak, D. P.; more...
Asia-Pacific Journal of Clinical Oncology (2017)

Fulltext@MSK | Save

Health-related quality of life (HRQoL) of pembrolizumab vs chemotherapy for previously treated advanced urothelial cancer (UC) in KEYNOTE-045

Meeting Abstract

Quinn, D.; Vaughn, D. J.; Bellmunt, J.; de Wit, R.; Fradet, Y.; Lee, J. L.; Fong, L.; Vogelzang, N. J.; Climent, M. A.; Petrylak, D. P.; more...
Asia-Pacific Journal of Clinical Oncology (2017)

Fulltext@MSK | Save

Pembrolizumab vs investigator-choice chemotherapy for previously treated advanced urothelial cancer: Phase 3 KEYNOTE-045 study

Meeting Abstract

Necchi, A.; Bellmunt, J.; De Wit, R.; Vaughn, D.; Fradet, Y.; Lee, J. L.; Fong, L.; Vogelzang, N.; Climent, M.; Petrylak, D.; more...
European Journal of Cancer (2017)

Fulltext@MSK | Save

Next-generation sequencing of nonmuscle invasive bladder cancer reveals potential biomarkers and rational therapeutic targets

Journal Article

Pietzak, E. J.; Bagrodia, A.; Cha, E. K.; Drill, E. N.; Iyer, G.; Isharwal, S.; Ostrovnaya, I.; Baez, P.; Li, Q.; Berger, M. F.; more...
European Urology (2017)

Fulltext@MSK | Save

First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): A multicentre, single-arm, phase 2 study

Journal Article

Balar, A. V.; Castellano, D.; O'Donnell, P. H.; Grivas, P.; Vuky, J.; Powles, T.; Plimack, E. R.; Hahn, N. M.; de Wit, R.; Pang, L.; more...
Lancet Oncology (2017)

Fulltext@MSK | Save

Subgroup analyses from KEYNOTE-045: Pembrolizumab (pembro) versus individual investigator's choice of chemotherapy (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (uc)

Meeting Abstract

Petrylak, D.; Vogelzang, N. J.; Fradet, Y.; Bajorin, D.; de Wit, R.; Vaughn, D. J.; Lee, J. L.; Fong, L.; Climent, M. A.; Necchi, A.; more...
Annals of Oncology (2017)

Fulltext@MSK | Save

Pembrolizumab (pembro) as first-line therapy in cisplatin-ineligible advanced urothelial cancer (UC): Outcomes from KEYNOTE-052 in senior patients (pts) with poor performance status

Meeting Abstract

Grivas, P.; Plimack, E.; Balar, A. V.; Castellano, D.; O'Donnell, P. H.; Bellmunt, J.; Powles, T.; Hahn, N.; de Wit, R.; Bajorin, D.; more...
Annals of Oncology (2017)

Fulltext@MSK | Save